{"doi":"10.3390/cancers17060957","title":"Humanized Anti-MUC16 Antibody-Conjugated Contrast Agents for Magnetic Resonance Imaging of Pancreatic Cancer","abstract":"Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is diagnosed at a late stage with distant metastasis in an overwhelming 50% of cases, and the prognosis is poor. Treating this extremely aggressive disease with standard-of-care therapies has led to modest benefits in overall survival, mainly due to a lack of targeted early treatment modalities, as early detection has not yet been possible. Mucin-16 (MUC16) is a glycoprotein overexpressed in more than 60% of patients with PDAC and is a tumor-specific biomarker. Methods: In this study, a magnetic resonance imaging (MRI) probe to facilitate the detection of early and late lesions of PDAC is developed by conjugating a MUC16-targeted humanized antibody (huAR9.6) with gadolinium. Results: In preclinical mouse models, this MUC16-targeted MRI probe demonstrates effective contrast enhancement in early lesions of PDAC in the subcutaneous setting and allows for the detection of late-stage pancreatic cancer tumors in an orthotopic model. The probe did not induce any toxicity in vital organs at the administered doses. Conclusions: This study establishes that synthesizing a MUC16-targeted MRI probe is feasible and allows for the better high-resolution contrast enhancement of MUC16+ PDAC lesions to facilitate detection and possibly better treatment strategies.","journal":"Cancers","year":2025,"id":550302,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9549,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":903098,"name":"Christabelle Rajesh","orcid":"0000-0001-5211-4454","position":1,"is_corresponding":false},{"id":903099,"name":"Satish Sagar","orcid":"0000-0002-6608-3940","position":2,"is_corresponding":false},{"id":264862,"name":"Thomas C. Caffrey","orcid":"0000-0001-6707-8468","position":3,"is_corresponding":false},{"id":783510,"name":"Ying Huang","orcid":"0000-0001-5783-0273","position":4,"is_corresponding":false},{"id":337360,"name":"Aaron M. Mohs","orcid":"0000-0002-9353-5404","position":5,"is_corresponding":false},{"id":1231146,"name":"Benjamin Swanson","orcid":"0009-0007-3887-9128","position":6,"is_corresponding":false},{"id":13563,"name":"Michael A. Hollingsworth","orcid":"0000-0002-5255-8888","position":7,"is_corresponding":false},{"id":664753,"name":"Cory L. Brooks","orcid":"0000-0002-6745-6526","position":8,"is_corresponding":false},{"id":230468,"name":"Prakash Radhakrishnan","orcid":"0000-0001-5314-1630","position":9,"is_corresponding":false},{"id":1445574,"name":"Jayasindu Mathiyazhagan","orcid":"0000-0001-7368-2688","position":0,"is_corresponding":true}],"reference_count":46,"raw_metadata":null,"created_at":"2026-07-19T02:54:16.596730Z","pmid":"40149293","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}